Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Efficacy and Safety of Ertugliflozin Monotherapy in the Treament of Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise
(1) Objective: At Week 26, to assess the effect on HbA1c of 15 mg ertugliflozin as compared with placebo. Hypothesis: At Week 26, the mean reduction from baseline in HbA1c for 15 mg ertugliflozin is...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subjects 60 years of age and older
1. To determine whether ZOSTAVAX™ administered concomitantly with PNEUMOVAX™ 23 elicits a VZV antibody response that is noninferior to that of ZOSTAVAX™ administered nonconcomitantly. 2. To demonst...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck KGaA (Germany)
Update Il y a 4 ans
Radiotherapy (intensity-modulated radiation therapy [IMRT]), Erbitux® And CHemotherapy for unresectable carcinomas of head and neck
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Ltd
Update Il y a 4 ans
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0822 in Patients with Osteoarthritis
1) To evaluate the efficacy of MK-0822 5 mg once daily relative to placebo in the prevention of knee cartilage loss over 12 months of treatment based on MRI assessments of cartilage normalized volume ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck-Serono
Update Il y a 4 ans
Merck ADVANTAGE : Essai de phase 1-2 randomisé évaluant l’efficacité et la tolérance de différents schémas d’association du cilengitide ou cisplatine, 5-FU et cétuximab, chez des patients ayant un cancer à cellules squameuses de la tête et du cou en rechute ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose la plus adaptée de cilengitide à administrer en association avec du cisplatine, du 5-FU et du cétuximab, puis d’évaluer l’efficacité de cette associat...
Country
France
organs
Tête et cou
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Ensayo aleatorizado, de adaptación y con dos partes de ridaforolimus combinado con dalotuzumab en comparación con exemestano o en comparación con ridaforolimus o dalotuzumab en monoterapia en pacientes con cáncer de mama con receptores estrogénicos positivos";"A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients
En la parte A de este estudio, el objetivo principal es evaluar la eficacia de la combinación de ridaforolimus y dalotuzumab en comparación con exemestano mediante el análisis de la supervivencia sin ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
V212 Lot Consistency Study
To determine whether V212 from three consistency lots have similar immunogenicity.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma
To determine the duration of PFS in patients with multiple myeloma, after at least 1 prior treatment regimen, treated with bortezomib and vorinostat compared to patients treated with bortezomib and pl...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Laboratoires Merck Sharp & Dohme - Chibret
Update Il y a 4 ans
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patients With Chronic Hepatitis C Infection
To evaluate the activity, as measured by the proportion of patients achieving RVR (undetectable viral load at Week 4), and the safety and tolerability, as assessed by review of the accumulated safety ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Serono Norway
Update Il y a 4 ans
ENDURE: A Phase IV, prospective, open-label, uncontrolled, multi-centre cohort trial to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 mg/kg/day for 28 days
The primary objective of the study is to evaluate the proportion of responders (≥30% reduction from baseline in blood Phe level) to 20 mg/kg/day Sapropterin dihydrochloride treatment at several time p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
7
8
9
10
11
12
13
14
15
16
Next